Terms: = Ovarian cancer AND CDK4, PSK-J3, 1019, ENSG00000135446, MGC14458, CMM3, P11802
219 results:
1. The Clinicopathological Significance of the Cyclin D1/E1-Cyclin-Dependent Kinase (CDK2/4/6)-Retinoblastoma (RB1/pRB1) Pathway in Epithelial ovarian cancers.
Lashen A; Algethami M; Alqahtani S; Shoqafi A; Sheha A; Jeyapalan JN; Mongan NP; Rakha EA; Madhusudan S
Int J Mol Sci; 2024 Apr; 25(7):. PubMed ID: 38612869
[TBL] [Abstract] [Full Text] [Related]
2. [A Case Report of Metastatic Breast cancer with Peritoneal Metastasis and Massive Ascites Responding to cdk4/6 Inhibitor(Palbociclib)].
Yao S; Goi T; Takahashi M; Kono H; Yokoi S; Maeda H
Gan To Kagaku Ryoho; 2024 Feb; 51(2):214-216. PubMed ID: 38449417
[TBL] [Abstract] [Full Text] [Related]
3. Major clinical research advances in gynecologic cancer in 2023: a tumultuous year for endometrial cancer.
Shim SH; Lee JY; Lee YY; Park JY; Lee YJ; Kim SI; Han GH; Yang EJ; Noh JJ; Yim GW; Son JH; Kim NK; Kim TH; Kong TW; Choi YJ; Cho A; Lim H; Jang EB; Cho HW; Suh DH
J Gynecol Oncol; 2024 Mar; 35(2):e66. PubMed ID: 38330382
[TBL] [Abstract] [Full Text] [Related]
4. [Recurrent Breast cancer with Bone Metastasis Effectively Treated with Abemaciclib plus Endocrine Therapy-A Case Report].
Adachi K; Nagae J; Kubota H; Suzuki S; Hirano T; Sakurai K
Gan To Kagaku Ryoho; 2023 Dec; 50(13):1845-1847. PubMed ID: 38303227
[TBL] [Abstract] [Full Text] [Related]
5. ER-positive and BRCA2-mutated breast cancer: a literature review.
Li PC; Zhu YF; Cao WM; Li B
Eur J Med Res; 2024 Jan; 29(1):30. PubMed ID: 38184581
[TBL] [Abstract] [Full Text] [Related]
6. Small-molecule inhibition of kinesin KIF18A reveals a mitotic vulnerability enriched in chromosomally unstable cancers.
Payton M; Belmontes B; Hanestad K; Moriguchi J; Chen K; McCarter JD; Chung G; Ninniri MS; Sun J; Manoukian R; Chambers S; Ho SM; Kurzeja RJM; Edson KZ; Dahal UP; Wu T; Wannberg S; Beltran PJ; Canon J; Boghossian AS; Rees MG; Ronan MM; Roth JA; Minocherhomji S; Bourbeau MP; Allen JR; Coxon A; Tamayo NA; Hughes PE
Nat Cancer; 2024 Jan; 5(1):66-84. PubMed ID: 38151625
[TBL] [Abstract] [Full Text] [Related]
7. The promise of combining cdk4/6 inhibition with hormonal therapy in the first-line treatment setting for metastatic or recurrent endometrial adenocarcinoma.
Ray-Coquard I; Monk BJ; Lorusso D; Mahdi H; Upadhyay V; Graul R; Husain A; Mirza MR; Slomovitz B
Int J Gynecol Cancer; 2023 Dec; 33(12):1943-1949. PubMed ID: 37907262
[TBL] [Abstract] [Full Text] [Related]
8. Mesonephric-like adenocarcinoma harbours characteristic copy number variations and a distinct DNA methylation signature closely related to mesonephric adenocarcinoma of the cervix.
Kommoss FK; Lee CH; Tessier-Cloutier B; Gilks CB; Stewart CJ; von Deimling A; Köbel M
J Pathol; 2024 Jan; 262(1):4-9. PubMed ID: 37850576
[TBL] [Abstract] [Full Text] [Related]
9. Clinicopathologic Analysis and Molecular Profiling of ovarian Steroid Cell Tumors.
Mendoza RP; Wang P; Smith HL; Fitzpatrick CA; Haridas R; Wanjari P; Briese R; Shahid A; McCluggage WG; Bennett JA
Am J Surg Pathol; 2023 Dec; 47(12):1398-1408. PubMed ID: 37796179
[TBL] [Abstract] [Full Text] [Related]
10. New Developments in Systemic Management for High-Risk Early-Stage Hormone-Receptor-Positive, HER2-Negative Breast cancer.
Brett JO; Mayer EL
Curr Treat Options Oncol; 2023 Jun; 24(6):594-610. PubMed ID: 37060423
[TBL] [Abstract] [Full Text] [Related]
11. Discovery of
Fanta BS; Lenjisa J; Teo T; Kou L; Mekonnen L; Yang Y; Basnet SKC; Hassankhani R; Sykes MJ; Yu M; Wang S
Molecules; 2023 Mar; 28(7):. PubMed ID: 37049714
[TBL] [Abstract] [Full Text] [Related]
12. [Arguments for centralization of surgical treatment of ovarian cancer in France based on morbidity and mortality data].
Meurette J; Daraï E; Tajahmady A; Fouard A; Ducastel A; Collin-Bund V; Jochum F; Lecointre L; Querleu D; Akladios C
Bull Cancer; 2024 Mar; 111(3):239-247. PubMed ID: 36797128
[TBL] [Abstract] [Full Text] [Related]
13. Effects of MFG-E8 expression on the biological characteristics of ovarian cancer cells via the AKT/mTOR/S6K signalling pathway.
Li N; Wang Y; Liu L; Wang P; Wu X
J Obstet Gynaecol; 2023 Dec; 43(1):2151354. PubMed ID: 36484512
[TBL] [Abstract] [Full Text] [Related]
14. Targeting the FGF/FGFR axis and its co-alteration allies.
Uehara Y; Ikeda S; Kim KH; Lim HJ; Adashek JJ; Persha HE; Okamura R; Lee S; Sicklick JK; Kato S; Kurzrock R
ESMO Open; 2022 Dec; 7(6):100647. PubMed ID: 36455506
[TBL] [Abstract] [Full Text] [Related]
15. Phase I trial of ribociclib with platinum chemotherapy in ovarian cancer.
Coffman LG; Orellana TJ; Liu T; Frisbie LG; Normolle D; Griffith K; Uppal S; McLean K; Berger J; Boisen M; Courtney-Brooks M; Edwards RP; Lesnock J; Mahdi H; Olawaiye A; Sukumvanich P; Taylor SE; Buckanovich R
JCI Insight; 2022 Sep; 7(18):. PubMed ID: 35972817
[TBL] [Abstract] [Full Text] [Related]
16. Treatment of Breast cancer in Young Adults.
Tesch ME; Partridge AH
Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-12. PubMed ID: 35580291
[TBL] [Abstract] [Full Text] [Related]
17. A Novel cdk4/6 and PARP Dual Inhibitor ZC-22 Effectively Suppresses Tumor Growth and Improves the Response to Cisplatin Treatment in Breast and ovarian cancer.
Tian C; Wei Y; Li J; Huang Z; Wang Q; Lin Y; Lv X; Chen Y; Fan Y; Sun P; Xiang R; Chang A; Yang S
Int J Mol Sci; 2022 Mar; 23(5):. PubMed ID: 35270034
[TBL] [Abstract] [Full Text] [Related]
18. The Immunological Role of cdk4/6 and Potential Mechanism Exploration in ovarian cancer.
Liu C; Huang Y; Cui Y; Zhou J; Qin X; Zhang L; Li X; Li Y; Guo E; Yang B; Li X; Fan J; Li X; Fu Y; Liu S; Hu D; Xiao R; Wang Z; Dou Y; Wang W; Li W; Yang X; Liu J; Peng W; Qin T; You L; Lu F; Sun C
Front Immunol; 2021; 12():799171. PubMed ID: 35095879
[TBL] [Abstract] [Full Text] [Related]
19. Prospective Analyses of Sedentary Behavior in Relation to Risk of ovarian cancer.
Buras AL; Wang T; Whiting J; Townsend MK; Fridley BL; Tworoger SS
Am J Epidemiol; 2022 May; 191(6):1021-1029. PubMed ID: 35094053
[TBL] [Abstract] [Full Text] [Related]
20. MS275 as Class I HDAC inhibitor displayed therapeutic potential on malignant ascites by iTRAQ-based quantitative proteomic analysis.
Du L; Wang D; Wei X; Liu C; Xiao Z; Qian W; Song Y; Hou X
BMC Gastroenterol; 2022 Jan; 22(1):29. PubMed ID: 35062876
[TBL] [Abstract] [Full Text] [Related]
[Next]
